Staging of cardiac rejection by simultaneous administration of 123I-antimyosin and 111In-anti MHC class II antibodies.
Noninvasive diagnosis of cardiac rejection before the advent of myocyte necrosis is important in clinical management of cardiac transplantation. Mice with abdominal heart transplants were studied to determine whether a dual scintigraphy using antimyosin and anti-major histocompatibility complex (MHC) class II antigen monoclonal antibody (mAb) labeled with different isotopes allows to detect early rejection just before myocyte necrosis. Allografts from BALB/c donors were transplanted into C3H/He recipients. Mice were intravenously injected with 100 microCi each of 123I labeled antimyosin and 111In labeled anti-MHC class II mAbs and were sacrificed for gamma counting from 2 to 9 days after transplantation. Localization of two different isotopes was compared with histological degree of acute rejection. Uptake of 111In labeled anti-MHC class II mAb increased from the fourth day after transplantation, however, that of 123I labeled antimyosin mAb was shown only 9 days after transplantation. Induction of MHC class II antigen develops preceding the development of myocyte necrosis, and this difference in time course can be identified by the dual scintigraphy. Thus, dual scintigraphy using anti-myosin and anti-MHC class II mAbs is potentially useful in staging of cardiac rejection.